Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis

Henry F. McFarland, Joseph A. Frank, Paul S. Albert, Mary E. Smith, Roland Martin, Jonathan O. Harris, Nicholas Patronas, Heidi Maloni, Dale E. McFarlin

Research output: Contribution to journalArticle

Abstract

The highly variable clinical course and the lack of a direct measurement of disease activity have made evaluation of experimental therapies in multiple sclerosis (MS) difficult. Recent studies indicate that clinically silent lesions can be demonstrated by magnetic resonance imaging (MRI) in patients with mild relapsing-remitting MS. Thus, MRI may provide a means for monitoring therapeutic trials in the early phase of MS. We studied 12 patients longitudinally for 12 to 21 months with monthly gadolinium (Gd)-enhanced MRIs. The data have been used to identify the most effective design of a clinical trial using Gd-enhanced lesions as the outcome measure. Frequent (>1/mo) Gd-enhancing lesions were observed in 9 of the 12 patients, indicating that the disease is active even during the early phase of the illness. The frequency of the lesions was not constant; there was marked fluctuation in lesion number from month to month. However, the magnitude of the peak number of lesions and the frequency of the peaks varied among patients. Because of this variability, the most effective use of Gd-enhancing lesions as an outcome measure in a clinical trial was a crossover design with study arms of sufficient duration to allow accurate estimation of lesion frequency. Monitoring Gd-enhancing lesions may be an effective tool to assist in the assessment of experimental therapies in early MS.

Original languageEnglish (US)
Pages (from-to)758-766
Number of pages9
JournalAnnals of Neurology
Volume32
Issue number6
StatePublished - Dec 1992
Externally publishedYes

Fingerprint

Gadolinium
Multiple Sclerosis
Magnetic Resonance Imaging
Investigational Therapies
Outcome Assessment (Health Care)
Clinical Trials
Relapsing-Remitting Multiple Sclerosis
Cross-Over Studies

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

McFarland, H. F., Frank, J. A., Albert, P. S., Smith, M. E., Martin, R., Harris, J. O., ... McFarlin, D. E. (1992). Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Annals of Neurology, 32(6), 758-766.

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. / McFarland, Henry F.; Frank, Joseph A.; Albert, Paul S.; Smith, Mary E.; Martin, Roland; Harris, Jonathan O.; Patronas, Nicholas; Maloni, Heidi; McFarlin, Dale E.

In: Annals of Neurology, Vol. 32, No. 6, 12.1992, p. 758-766.

Research output: Contribution to journalArticle

McFarland, HF, Frank, JA, Albert, PS, Smith, ME, Martin, R, Harris, JO, Patronas, N, Maloni, H & McFarlin, DE 1992, 'Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis', Annals of Neurology, vol. 32, no. 6, pp. 758-766.
McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Annals of Neurology. 1992 Dec;32(6):758-766.
McFarland, Henry F. ; Frank, Joseph A. ; Albert, Paul S. ; Smith, Mary E. ; Martin, Roland ; Harris, Jonathan O. ; Patronas, Nicholas ; Maloni, Heidi ; McFarlin, Dale E. / Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. In: Annals of Neurology. 1992 ; Vol. 32, No. 6. pp. 758-766.
@article{2657fe7cc0e4420fb8ee4c0edd7854e0,
title = "Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis",
abstract = "The highly variable clinical course and the lack of a direct measurement of disease activity have made evaluation of experimental therapies in multiple sclerosis (MS) difficult. Recent studies indicate that clinically silent lesions can be demonstrated by magnetic resonance imaging (MRI) in patients with mild relapsing-remitting MS. Thus, MRI may provide a means for monitoring therapeutic trials in the early phase of MS. We studied 12 patients longitudinally for 12 to 21 months with monthly gadolinium (Gd)-enhanced MRIs. The data have been used to identify the most effective design of a clinical trial using Gd-enhanced lesions as the outcome measure. Frequent (>1/mo) Gd-enhancing lesions were observed in 9 of the 12 patients, indicating that the disease is active even during the early phase of the illness. The frequency of the lesions was not constant; there was marked fluctuation in lesion number from month to month. However, the magnitude of the peak number of lesions and the frequency of the peaks varied among patients. Because of this variability, the most effective use of Gd-enhancing lesions as an outcome measure in a clinical trial was a crossover design with study arms of sufficient duration to allow accurate estimation of lesion frequency. Monitoring Gd-enhancing lesions may be an effective tool to assist in the assessment of experimental therapies in early MS.",
author = "McFarland, {Henry F.} and Frank, {Joseph A.} and Albert, {Paul S.} and Smith, {Mary E.} and Roland Martin and Harris, {Jonathan O.} and Nicholas Patronas and Heidi Maloni and McFarlin, {Dale E.}",
year = "1992",
month = "12",
language = "English (US)",
volume = "32",
pages = "758--766",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis

AU - McFarland, Henry F.

AU - Frank, Joseph A.

AU - Albert, Paul S.

AU - Smith, Mary E.

AU - Martin, Roland

AU - Harris, Jonathan O.

AU - Patronas, Nicholas

AU - Maloni, Heidi

AU - McFarlin, Dale E.

PY - 1992/12

Y1 - 1992/12

N2 - The highly variable clinical course and the lack of a direct measurement of disease activity have made evaluation of experimental therapies in multiple sclerosis (MS) difficult. Recent studies indicate that clinically silent lesions can be demonstrated by magnetic resonance imaging (MRI) in patients with mild relapsing-remitting MS. Thus, MRI may provide a means for monitoring therapeutic trials in the early phase of MS. We studied 12 patients longitudinally for 12 to 21 months with monthly gadolinium (Gd)-enhanced MRIs. The data have been used to identify the most effective design of a clinical trial using Gd-enhanced lesions as the outcome measure. Frequent (>1/mo) Gd-enhancing lesions were observed in 9 of the 12 patients, indicating that the disease is active even during the early phase of the illness. The frequency of the lesions was not constant; there was marked fluctuation in lesion number from month to month. However, the magnitude of the peak number of lesions and the frequency of the peaks varied among patients. Because of this variability, the most effective use of Gd-enhancing lesions as an outcome measure in a clinical trial was a crossover design with study arms of sufficient duration to allow accurate estimation of lesion frequency. Monitoring Gd-enhancing lesions may be an effective tool to assist in the assessment of experimental therapies in early MS.

AB - The highly variable clinical course and the lack of a direct measurement of disease activity have made evaluation of experimental therapies in multiple sclerosis (MS) difficult. Recent studies indicate that clinically silent lesions can be demonstrated by magnetic resonance imaging (MRI) in patients with mild relapsing-remitting MS. Thus, MRI may provide a means for monitoring therapeutic trials in the early phase of MS. We studied 12 patients longitudinally for 12 to 21 months with monthly gadolinium (Gd)-enhanced MRIs. The data have been used to identify the most effective design of a clinical trial using Gd-enhanced lesions as the outcome measure. Frequent (>1/mo) Gd-enhancing lesions were observed in 9 of the 12 patients, indicating that the disease is active even during the early phase of the illness. The frequency of the lesions was not constant; there was marked fluctuation in lesion number from month to month. However, the magnitude of the peak number of lesions and the frequency of the peaks varied among patients. Because of this variability, the most effective use of Gd-enhancing lesions as an outcome measure in a clinical trial was a crossover design with study arms of sufficient duration to allow accurate estimation of lesion frequency. Monitoring Gd-enhancing lesions may be an effective tool to assist in the assessment of experimental therapies in early MS.

UR - http://www.scopus.com/inward/record.url?scp=0026474514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026474514&partnerID=8YFLogxK

M3 - Article

C2 - 1471866

AN - SCOPUS:0026474514

VL - 32

SP - 758

EP - 766

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 6

ER -